Results about: tech transfer

A study reveals the effectiveness of a cognitive enhancer for schizophrenia treatment

Compound IPR19, a drug to stop the progression and reverse the cognitive deficits associated with schizophrenia.

Tumour cells are dependent on fat to start metastasis

A study at IRB Barcelona has identified the cells responsible for initiating and promoting metastasis in several types of human tumours.

Their results show that the protein CD36, which absorbs fat from the cell membrane, is an essential factor that determines whether tumour cells become metastatic.

In the absence of CD36, the human tumours analysed did not develop metastasis. In addition, the inhibition of this protein also dramatically reduced the size of existing metastases.

Mice given a high-fat diet developed the most aggressive metastases. The study reports that the metastatic process is enhanced by fat intake.

IRB Barcelona will co-develop antibodies against CD36 with the potential to treat patients.

Scientists set to become entrepreneurs

IRB Barcelona fosters entrepreneurship among its young scientists. Two postdoctoral fellows tell in vivo about their experience of learning how to deal with markets, patents and venture capitalists. 

IRB Barcelona strengthens its ties with industry through participation in BioSpain

The Bilbao Exhibition Center (BEC) in Barakaldo (Vizcaya) is the venue of BioSpain 2016, the eighth of these biennial biotech gatherings, the most important event in this sector in Europe and permanently held in Spain, and fifth-ranked event worldwide for the number of partnering meetings held.

Launch of Nostrum BioDiscovery, a spin-off that applies supercomputing to speed up drug discovery

Nostrum BioDiscovery has come about from the combined efforts of IRB Barcelona and the BSC-CNS—two research centres of excellence in Barcelona—with the participation of the University of Barcelona and ICREA and supported by the Botín Foundation’s technology transfer programme.

The company boasts cutting-edge bioinformatics technologies to speed up the development and lower the cost of designing drugs—which are becoming increasingly more complex and expensive—and to further precision medicine.